Berenberg Downgrades Evotec to 'Hold' as Delayed Deals Force Guidance Cut

Berenberg downgraded Evotec SE to “Hold” from “Buy” and slashed its price target after the German biotech firm sharply reduced its full-year 2026 financial guidance, citing delays in signing major partnership deals. The brokerage pointed to a lack of near-term visibility as the primary driver for the ratings change, which sent the company's shares lower.

Guidance Cut Prompts Downgrade

Following the announcement, Berenberg cut its price target on Evotec to €3.60 from a previous €9.40. The move was a direct response to Evotec's revised outlook, which fell significantly short of market expectations.

Evotec's new guidance for fiscal year 2026 includes:

• Group revenue of €570 million to €610 million, well below the prior consensus estimate of €730 million.
• Adjusted group EBITDA of negative €70 million to negative €105 million, a stark reversal from the consensus forecast for a positive €33 million.

Delayed Deals and Uncertain Timing

Ad

According to Berenberg's note, Evotec management characterized the guidance revision as a timing issue rather than a structural problem. The company stated that prolonged sales cycles have pushed anticipated revenues from major partnerships into 2027. The new, lower guidance is based only on existing contracts with high confidence levels.

However, the uncertainty prompted the ratings action. "As it stands, we believe the phasing of important partnerships is uncertain," wrote Berenberg analyst Christian Ehmann, citing the limited visibility as the reason for the downgrade. The brokerage said the core investment thesis now hinges on management's ability to convert its pipeline of 20 large pharma opportunities into revenue next year.

Analyst Revisions and Segment Concerns

Berenberg also flagged underlying performance issues, noting a 16% year-over-year revenue decline in Evotec’s Discovery & Preclinical Development segment for the first half of 2026, which it said "casts doubt on the organic growth narrative."

In response to the new outlook, Berenberg has significantly lowered its own forecasts, cutting its 2026 sales estimate for Evotec by 18.7%. While the company's "Horizon" cost-saving program remains on track, Berenberg stated that these measures are "insufficient to offset delayed high-margin partnership revenue."